CytoDyn Inc. CYDY
0.25 USD +0.01 (+4.17%)
Regular-session close
0.24 Day range 0.2533
0.19 52-week range 0.37
- YTD
- -10.71%
- 1 year
- 0.00%
- Market cap
- 367.38M
- EPS (ttm)
- -0.03
- YTD return
- -10.71%
- 1-year return
- 0.00%
- Volume
- 976.73K
- Avg volume
- 1.86M
- Open
- 0.2413
- Previous close
- 0.24
- Day's range
- 0.24 – 0.2533
- 52-week range
- 0.19 – 0.37
5D +0.0199 (+8.65%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 21, 2025 | Nov 1, 2024 | 0.00 | — | — | — |
| Oct 15, 2024 | Aug 1, 2024 | 0.00 | 0.02 | — | — |
| Aug 15, 2024 | May 1, 2024 | 0.00 | -0.02 | — | — |
| Apr 15, 2024 | Feb 1, 2024 | 0.00 | -0.01 | — | — |
| Jan 16, 2024 | Nov 1, 2023 | 0.00 | -0.01 | — | — |
| Oct 23, 2023 | Aug 1, 2023 | 0.00 | -0.01 | — | — |
News
CytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors 
CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer 
CytoDyn (OTCMKTS:CYDY) Shares Break Below Two Hundred Day Moving Average – Here’s What Happened 
CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026 
CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript 
CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO 
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer 
CytoDyn to Host Investor Webcast 
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026 
CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer
Your note
Sign in to keep a note on CYDY — it syncs with the Stock Master app.